ArticleScientific reports2025
Machine learning identifies inflammation-related diagnostic biomarkers for primary myelofibrosis with clinical validation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Primary myelofibrosis (PMF) is a heterogeneous bone marrow disorder, and substantial evidence indicates the involvement of inflammatory mediators in its progression. However, a diagnostic model based on inflammation-related genes has not yet been established. The aim of this study was to identify specific inflammation-related genes (IRGs) with potential value in myelofibrosis diagnosis and risk prediction. Transcriptomic data from the Gene Expression Omnibus (GEO) database were analysed to identify inflammation-related differentially expressed genes (DEGs). Machine learning approaches, including the least absolute shrinkage and selection operator (LASSO) and random forest, were used to select hub genes. A nomogram was constructed and validated externally using independent GEO datasets and local sequencing data. Immune cell infiltration and functional enrichment were also investigated. HBEGF, TIMP1 and PSEN1 show significant differences in expression between normal individuals and those with PMF. A nomogram based on three genes was established to assess the risk of PMF in healthy individuals. The ROC curve revealed that the three hub genes have outstanding diagnostic value for this disease (AUC = 0.994; 95% CI: 0.985-1.000); the results were subsequently validated in an external validation set (AUC = 0.807; 95% CI: 0.723-0.891), and a sequencing dataset from the First Affiliated Hospital of Zhejiang University (AUC = 0.982; 95% CI: 0.841-1). Enrichment analyses implicated cancer-related and immune pathways, and the model genes correlated significantly with immune cell infiltration and function. We developed and validated a robust three gene diagnostic model for PMF based on inflammation-related genes, offering a noninvasive molecular tool with potential clinical utility for auxiliary diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.